In this episode of OncTimes Talk, we chat with Sami Mansfield, ACSM-CET, PN1, the founder of Cancer Wellness for Life, an organization dedicated to developing, implementing, and optimizing exercise oncology and lifestyle medicine programs and resources for hospitals, healthcare organizations, pharmaceutical companies, nonprofits, and individuals impacted by cancer.

cancerwellnessforlife.com

In this episode of OncTimes Talk, we chat with Katie Coleman. Diagnosed with an ultra-rare stage IV kidney cancer in 2020, her prognosis had a chance to significantly change after six months. Since then, Katie has since become an Author, founded a non-profit organization, and has become a podcast host—all with the goal of giving back to cancer research.

Katiekickscancer.com

In this episode of the OncTimes Talk, we chat with Susan MacDonald, MD, Associate Professor and Program Director of the Department of Urology at Penn State Health Milton S. Hershey Medical Center, in Hershey, PA.

MacDonald shares her inspiring journey of facing a life-changing diagnosis with strength and resilience. Discover her insights into the healthcare system, the unexpected joys she found, and her advice for others facing similar challenges.

In this episode of the OncTimes Talk, we chat with Susan MacDonald, MD, Associate Professor and Program Director of the Department of Urology at Penn State Health Milton S. Hershey Medical Center, in Hershey, PA.

MacDonald shares her inspiring journey of facing a life-changing diagnosis with strength and resilience. Discover her insights into the healthcare system, the unexpected joys she found, and her advice for others facing similar challenges.

Masood Moghul, MBBS, a urologist and Research Fellow at the Royal Marsden Hospital and Institute of Cancer Research in London shared findings from a study investigating a mobile, targeted, case-finding approach to prostate cancer detection with 3,379 patients.

Moghul told the 2025 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in San Francisco how the study addressed health inequalities and barriers to accessing health care that affect prostate cancer in high-risk underserved groups.

At the 2025 ASCO Genitourinary Cancers Symposium, researchers from Japan reported marked differences between the populations of several key microbial species in the gut microbiomes of patients with metastatic prostate cancer that distinguished them from those with non-metastatic disease. This was in the PROMISE-JAPAN study with 869 Japanese patients.

After talking about his group’s new data, lead researcher Koji Hatano, MD, a urologist from Osaka University in Japan, discussed the insights this has given doctors into the metastatic process and potential ways of modifying it.